Real-World Evidence of Automated Insulin Delivery System Use
Diabetes Technology & Therapeutics · 2024-03 · 26 (3_suppl) · 53-65
DOI: 10.1089/dia.2023.0442 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 05.02.2024. Verfasst von Elizabeth G Considine und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Infusion Systems, Insulin, Hypoglycemic Agents. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Objective
Pivotal trials of automated insulin delivery (AID) closed-loop systems have demonstrated a consistent picture of glycemic benefit, supporting approval of multiple systems by the Food and Drug Administration or Conformité Européenne mark receipt. To assess how pivotal trial findings translate to commercial AID use, a systematic review of retrospective real-world studies was conducted.
Methods
PubMed and EMBASE were searched for articles published after 2018 with more than five nonpregnant individuals with type 1 diabetes (T1D). Data were screened/extracted in duplicate for sample size, AID system, glycemic outcomes, and time in automation.
Results
Of 80 studies identified, 20 met inclusion criteria representing 171,209 individuals. Time in target range 70–180 mg/dL (3.9–10.0 mmol/L) was the primary outcome in 65% of studies, with the majority of reports (71%) demonstrating a >10% change with AID use. Change in hemoglobin A1c (HbA1c) was reported in nine studies (range 0.1%–0.9%), whereas four reported changes in glucose management indicator (GMI) with a 0.1%–0.4% reduction noted. A decrease in HbA1c or GMI of >0.2% was achieved in two-thirds of the studies describing change in HbA1c and 80% of articles where GMI was described. Time below range
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Elizabeth G Considine, Jennifer L Sherr
Förderung
- NCATS NIH HHS
Zitieren
APA
Considine, E. G., & Sherr, J. L. (2024). Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technology & Therapeutics, 26(3_suppl), 53-65. https://doi.org/10.1089/dia.2023.0442
Vancouver
Considine EG, Sherr JL. Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technology & Therapeutics. 2024;26(3_suppl):53-65. doi:10.1089/dia.2023.0442
BibTeX
@article{Considine2024,
author = {Considine, Elizabeth G and Sherr, Jennifer L},
title = {Real-World Evidence of Automated Insulin Delivery System Use},
journal = {Diabetes Technology & Therapeutics},
year = {2024},
volume = {26},
number = {3_suppl},
pages = {53--65},
doi = {10.1089/dia.2023.0442}
}
EUVIMED